04/18/2023
Anapharm Bioanalytics Secures Funding from Eurostars and CDTI for Innovative Project on Therapy and Diagnosis of Ewing Sarcoma
Barcelona, April 18th, 2023 - Anapharm Bioanalytics, a leading bioanalytical contract research organization (CRO), is delighted to announce the successful acquisition of funding from the Eurostars-3 joint program, with co-funding from CDTI (Centre for Industrial Technological Development) and the European Union's Horizon Europe Research and Innovation Framework. This funding marks a significant milestone for the groundbreaking project, a collaborative effort between Anapharm Bioanalytics, iCellate Medical, and Aptadel Therapeutics.
The project endeavours to develop an innovative therapy and complementary diagnostic for Ewing Sarcoma, a rare childhood cancer. The project's flagship product, ADEL-101, entails an RNA-based aptamer specifically designed to target Ewing Sarcoma cells, combined with an RNA drug that effectively eliminates these cancer cells. The project will encompass comprehensive analyses of the drug's efficacy, mode of action, safety, toxicology, and pharmacokinetics, alongside the development of a companion diagnostic.
Each consortium member plays a pivotal role in the project, contributing their expertise and capabilities. Anapharm Bioanalytics, a specialized bioanalytical CRO, will spearhead the development of a bioanalytical test aimed at tracking the drug candidate ADEL-101 within the body. iCellate Medical, a leading Swedish medtech company, will be instrumental in the creation of a companion diagnostic kit to ensure the safe and effective utilization of ADEL-101 in human patients. Additionally, Aptadel Therapeutics, a Spanish biotech company, brings their cutting-edge RNA aptamer-based technology to the consortium, facilitating the development of a new class of drug conjugates.
This project has received funding from the Eurostars-3 joint program with co-funding from CDTI and the Horizon Europe Research and Innovation Framework of the European Union. Subsidized by CDTI. The company extends its deepest gratitude to these institutions for their commitment to advancing innovative research in the field of Ewing Sarcoma. It is important to note that any communication or publication regarding the project reflects solely the opinions of the authors, and neither CDTI nor the European Commission bears responsibility for the use that may be made of the information contained therein.
MORE NEWS
Peptides Series: Understanding Therapeutic Peptides
Therapeutic peptides are transforming modern medicine thanks to their unique advantages over traditional drug therapies. Their molecular structure and biological properties allow them to achieve effects like natural molecules in the body, enabling targeted action with fewer risks of off-target effects.
The visit of the Mayor of Barcelona, Jaume Collboni, to Anapharm Bioanalytics
Last Friday, January 10th 2025, we had the honor of welcoming the Mayor of Barcelona, Jaume Collboni, to our facilities. His visit was a special opportunity for us to showcase the work we do at Anapharm Bioanalytics and to reaffirm our commitment to innovation in the field of bioanalysis.
Overcoming Matrix Effects in the Analysis of Lipophilic Compounds
At the 10th EBF Young Scientist Symposium, we highlighted the complexities of analysing Fucoxanthin derivatives and demonstrated how innovative approaches, such as 2D Chromatography, can overcome these obstacles.